MODERN TREATMENT OPTIONS OF TOENAIL ONYCHOMYCOSIS (A LITERATURE REVIEW)
https://doi.org/10.25207/1608-6228-2019-26-2-202-213
Abstract
Introduction. The importance of investigating the problem of toenail onychomycosis is associated not only with its widespread prevalence among the population and negative effects on the patient life quality, but also with signifi cant diffi culties arising during its therapy. At the moment, a large number of systemic and local antifungal drugs are successfully applied for treating this pathology. Moreover, new physiotherapeutic methods are being developed and introduced into clinical practice. These treatment approaches are based on different action mechanisms, thus demonstrating certain advantages and disadvantages.
Discussion. This article sets out to provide a review of antifungal drugs recommended for use in the Russian Federation in patients suffering from onychomycosis of the feet. The results of studies aimed at establishing the clinical effi cacy and application of azole, allylamine, morpholine and ciclopirox derivatives are summarized. Criteria for the selection of these drugs for systemic and local therapy are given. Both Russian and foreign recent publications devoted to physical factors in the treatment of fungal nail infections are analyzed. The action mechanisms, clinical effi cacy, application methods, signifi cant adverse effects of laser and photodynamic methods, as well as ultrasound, magnetic and electric fi elds, are described.
Conclusion. Modern approaches to the treatment of toenail onychomycosis are shown to use a large selection of systemic and local antifungal drugs, as well as physiotherapeutic methods for correcting this pathology. All of them have different action mechanisms characterized by particular advantages and disadvantages. To date, there is no universal drug for the treatment of toenail onychomycosis, which would affect all parts of the mycotic process. Following the analysis of recently published literature, it is shown that the use of topical medications and physiotherapy in combination not only signifi cantly reduces the duration of the application of systemic antimycotic drugs, but also expands the etiological indications and their adverse effects. Therefore, such a therapy is established to be the most effective approach to the treatment of toenail onychomycosis at the present stage.
About the Authors
Marina M. Tlish
Kuban State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Dr. Sci. (Med.), Assoc. Prof., Head of Department, Department of Dermatovenereology,
Mitrofanа Sedina str., 4, Krasnodar, 350063
Marina E. Shavilova
Kuban State Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Research Assistant, Department of Dermatovenereology,
Mitrofanа Sedina str., 4, Krasnodar, 350063
References
1. Nenoff P., Ginter-Hanselmayer G., Tietz H. J. Fungal nail infections — an update: Part 1 — Prevalence, epidemiology, predisposing conditions, and differential diagnosis. Hautarzt. 2012; 63(1): 30–38. DOI: 10.1007/s00105-011-2251-5
2. Kubanov A. A., Frigo N. V. Results of a multicenter screening study on etiological structure of onychomycosis pathogens in the Russian Federation. Vestnik Dermatologii i Venerologii. 2007; 4: 6–11 (In Russ.).
3. Tlish M. M., Kuznetsova T. G., Psavok F. A. Etiological features of onychomycosis in the Krasnodar territory. Choice of method systemic therapy. Vestnik Dermatologii i Venerologii. 2016; 5: 84–89 (In Russ., English abstract).
4. Gupta C., Das S., Ramachandran V. G., Saha R., Bhattacharya S. N., Dar S. A., Atri D. Possible role of trichophytin antigen in inducing impaired immunological clearance of fungus in onychomycosis. Mycopathologia. 2016; 181(3–4): 247–251. DOI: 10.1007/s11046-015-9973-3
5. Sokolova T. V., Malyarchuk T. A. Epidemiology of foot mycoses (literature review). Epidemiologiya i Vakcinoprofi laktika. 2015; 14(1)80: 70–74 (In Russ., English abstract).
6. Federal’nye klinicheskie rekomendatsii. Dermatovenerologiya 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem [Federal clinical guidelines. Dermatology 2015: diseases of the skin. Sexually transmitted infections]. 5th edition, recycled, augmented. M.: Delovoi ekspress; 2016: 768 (In Russ.).
7. Sergeev Yu. V. Mestnaya i kombinirovannaya terapiya onikhomikozov. Posobie dlya vrachei [Local and combination therapy of onychomycosis. Manual for doctors]. M.: Natsional’naya akademiya mikologii; 2013: 40 (In Russ.).
8. Marais A., Osuch E. Common cutaneous dermatophyte infections of the skin and nails. South African Family Practice. 2017; 59(3): 33–40.
9. Katsambas A. D., Lotti C., Dessinioti A. M., D’Erme T. M., editors. European handbook of dermatological treatments. Springer-Verlag Berlin Heidelberg; 2015: 1579.
10. Stepanova Zh. V. Mikozy: sovremennye podkhody k farmakoterapii [Mycoses: modern approaches to pharmacotherapy]. Trudnyi Patsient. 2005; 3(5): 36– 40 (In Russ.).
11. Willemsen M., de Doncker P., Wilíems J., Woestenborghs R., van de Velde V., Heykants J., Van Cutsem J., Cauwenbergh G., Roseeuw D. Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J. Am. Acad. Dermatol. 1992; 26(5 Pt 1): 731–735.
12. Ghannoum M. Azole Resistance in dermatophytes: prevalence and mechanism of action. J. Am. Podiatr. Med. Assoc. 2016; 106(1): 79–86. DOI: 10.7547/14- 109
13. Nett J. E., Andes D. R. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect. Dis. Clin. North Am. 2016; 30(1): 51–83. DOI: 10.1016/j.idc.2015.10.012
14. Brautigam M., Nolting S., Schopf R. E., Weidinger G. Randomized double blind comparison terbinafi ne itraconazole for treatment of toenail tinea infection. BMJ. 1995; 311(7010): 919–922.
15. Gupta A. K., Lynde C. M., Konnikow N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafi ne pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 2001; 44(3): 485–491. DOI: 10.1067/mjd.2001.110644
16. De Sá D. C., Lamas A. P., Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am. J. Clin. Dermatol. 2014; 15(1): 17–36. DOI: 10.1007/s40257-013-0056-2
17. Singal A., Khanna D. Onychomycosis: diagnosis and management. Indian J. Dermatol. Venereol. Leprol. 2011; 77(6): 659–672. DOI: 10.4103/0378- 6323.86475
18. Jellinek N. J. Understanding onychomycosis treatment: mechanisms of action and formulation. Semin. Cutan. Med. Surg. 2015; 34(3 Suppl): S51–53. DOI: 10.12788/j.sder.2015.0149
19. Motedayen N., Hashemi S. J., Rezaei S., Bayat M. In-vitro evaluation of antifungal activity of terbinafi ne and terbinafi ne nano-drug against clinical isolates of dermatophytes. Jundishapur. J. Microbiol. 2018; 11(5): е52351. DOI: 10.5812/jjm.62351
20. Gianni C. Update on antifungal therapy with terbinafine. G. Ital. Dermatol. Venereol. 2010; 145(3): 415– 424.
21. Gupta A. K., Nakrieko K. A. Trichophyton rubrum DNA strain switching increases in patients with onychomycosis failing antifungal treatments. Br. J. Dermatol. 2015; 172(1): 74–80. DOI: 10.1111/bjd.13165
22. Ryder N. S., Favre B. Antifungal activity and mechanism of action of terbinafi ne. Pharmacother. 1997; 8(5): 275–287.
23. Gupta A. K., Ryder J. E. The use of oral antifungal agents to treat onychomycosis. Dermatol. Clin. 2003; 21(3): 469–479.
24. Faergemann J. Pharmacokinetics of terbinafi ne. Rev. Contemp. Pharmacother. 1997; 8: 289–297.
25. De Doncker P. Pharmacokinetics in Onychomycosis. In: Jacobs P., Nall L., editors. Fungal Disease. M. Dekker, London; 1997: 530–537.
26. Faergemann J., Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekly. Acta. Derm. Venereol. 1996; 76(3): 219–221. DOI: 10.2340/0001555576219221
27. Sigurgeirsson B. Systemic therapy of onychomycosis. In: Rubin A. I., Jellinek N. J., Daniel C. R., Scher R. K., editors. Scher and Daniel’s Nails. Springer, Cham; 2018: 185–214.
28. Vlasova N. A., Rustamkhanova G. R., Khismatullina Z. R. Sostoyanie pechenochnogo metabolizma u bol’nykh onikhomikozami pod vliyaniem sistemnoi antimikoticheskoi terapii [The state of hepatic metabolism in patients with onychomycosis under the infl uence of systemic antimycotic therapy]. Doktor.RU. 2015; 2–2(103): 53–54 (In Russ.).
29. Sanguinetti M., Posteraro B., Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015; 58(2): 2–13. DOI: 10.1111/myc.12330
30. Lecha M., Effendy I., Feuilhade de Chauvin M., Di Chiacchio N., Baran R. Taskforce on onychomycosis education. Treatment options-development of consensus guidelines. J. Eur. Acad. Dermatol. Venereol. 2005; 19(Suppl 1): 25–33. DOI: 10.1111/j.1468-3083.2005.01284.x
31. Rosen T., Schell B. J., Orengo I. Anti-infl ammatory activity of antifungal preparations. Int. J. Dermatol. 1997; 36(10): 788–792.
32. Burkhart C. G., Burkhart C. N., Isham N. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. Br. J. Dermatol. 2006; 154(2): 341–344. DOI: 10.1111/j.1365-2133.2005.06924.x
33. Shemer A., Gupta A. K., Kamshov A., Babaev M., Farhi R., Daniel C. R., Foley K. A. Topical antifungal treatment prevents recurrence of toenail onychomycosis following cure. Dermatol. Ther. 2017; 30(5), e12545. DOI: 10.1111/dth.12545
34. Seidl H. P., Jäckel A., Müller J., Schaller M., Borelli C., Polak A. Sporicidal effect of amorolfi ne and other antimycotics used in the therapy of fungal nail infections. Mycoses. 2015; 58(10): 610–619. DOI: 10.1111/myc.12369
35. Ghelardi E., Celandroni F., Gueye S. A., Salvetti S., Senesi S., Bulgheroni A., Mailland F. Potential of Ergosterol synthesis inhibitors to cause resistance or cross-resistance in Trichophyton rubrum. Antimicrob. Agents Chemother. 2014; 58(5): 2825–2829. DOI: 10.1128/AAC.02382-13 3
36. Subissi A., Monti D., Togni G., Mailland F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs. 2010; 70(16): 2133– 2152. DOI: 10.2165/11538110-000000000-00000
37. Zaslavskii D. V., Chuprov I. N., Sydikov A. A., Khvedelidze M. G., Tatarskaya O. B. Onychomycosis: features external therapy. Vestnik Dermatologii i Venerologii. 2016; 5: 90–95 (In Russ., English abstract).
38. Sergeev Yu. V., Savchenko N. V., Sergeev A.Yu. Treating onychomycosis topically in the second decade of new millenium. Immunopatologiya, Allergologiya, Infektologiya. 2012; 3: 73–80 (In Russ., English abstract).
39. Kataria P., Sharma G., Thakur K., Bansal V., Dogra S., Katare O. P. Emergence of nail lacquers as potential transungual delivery system in the management of onchomycosis. Expert Opinion on Drug Delivery. 2016; 13(7): 937–952. DOI: 10.1080/17425247.2016.1174691
40. Francuzik W., Fritz K., Salavastru C. Laser therapies for onychomycosis — critical evaluation of methods and effectiveness. J. Eur. Acad. Dermatol.Venereol. 2016; 30(6): 936–942. DOI: 10.1111/jdv.13593
41. Ledon J. A., Savas J., Franca K., Chacon A., Nouri K. Laser and light therapy for onychomycosis: a systematic review. Lasers Med. Sci. 2014; 29(2): 823–829. DOI: 10.1007/s10103-012-1232-y
42. Lahiri K., De A., Sarda A., editors. Textbook of lasers in dermatology. 1st ed. Jaypee Brothers Medical Publishers; 2016: 334.
43. Gupta A. K., Simpson F. C., Heller D. F. The future of lasers in onychomycosis. J. Dermatolog. Treat. 2016; 27(2): 167–172. DOI: 10.3109/09546634.2015.1066479
44. Garazha S. N., Grishilova E. N., Demina K.Yu., Batchaeva D. D., Gotlib A. O., Brazhnikova A. N. Infl uence photodynamic and laser therapy on cytochemical activity neutrophilic granulocytes in chronic gingivitis. Kubanskii Nauchnyi Meditsinskii Vestnik. 2015; 150(1): 34–37 (In Russ., English abstract).
45. Zhang J., Lu S., Huang H., Li X., Cai W., Ma J., Xi L. Combination therapy for onychomycosis using a fractional 2940-nm Er: YAG laser and 5% amorolfi ne lacquer. Lasers Med. Sci. 2016; 31(7): 1391–1396. DOI: 10.1007/s10103-016-1990-z
46. Kim Y. R., Lee Y. W., Choe Y. B., Ahn K. J. Lack of antifungal effect of 1,064 nm long pulse Nd: YAG laser on the growth of Trichophyton rubrum. Lasers Med. Sci. 2015; 30(6): 1811–1813.
47. Issa M. C., Manela-Azulay M. Photodynamic therapy: a review of the literature and image documentation. An. Bras. Dermatol. 2010; 85(4): 501–511.
48. Smijs Т., Dame Z., de Haas E., Aans J. B., Pavel S., Sterenborg Н. Photodynamic and nail penetration enhancing effects of novel multifunctional photosensitizers designed for the treatment of onychomycosis. Photochem. Photobiol. 2014; 90(1): 189–200. DOI: 10.1111/php.12196
49. Threes G., Smijs М., Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on Trichophyton rubrum. Photochem. Photobiol. 2011; 87(1): 2–13. DOI: 10.1111/j.1751- 1097.2010.00848.x
50. Watanabe D., Kawamura C., Masuda Y., Akita Y., Tamada Y., Matsumoto Y. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch. Dermatol. 2008; 144(1): 19–21. DOI: 10.1001/archdermatol.2007.17
51. Bhatta A. K., Keyal U., Wang X. L. Photodynamic therapy for onychomycosis: A systematic review. Photodiagnosis Photodyn. Ther. 2016; 15: 228–235. DOI: 10.1016/j.pdpdt.2016.07.010
52. Smijs T. G., Bouwstra J. A., Talebi M., Pavel S. Investigation of conditions involved in the susceptibility of the dermatophyte Trichophyton rubrum to photodynamic treatment. J. Antimicrob. Chemother. 2007; 60(4): 750–759. DOI: 10.1093/jac/dkm304
53. Amichai B., Nitzan B., Mosckovitz R., Shemer A. Iontophoretic delivery of terbinafi ne in onychomycosis: a preliminary study. Br. J. Dermatol. 2010; 162(1): 46– 50. DOI: 10.1111/j.1365-2133.2009.09414.x
54. Trufanov D. A., Raigorodskii Yu. M. Opyt primeneniya «Alom» dlya mestnoi terapii onikhomikozov stop [Experience of application of «Allom» for the topical treatment of toenail onychomycosis]. Poliklinika. 2008; 1: 64–66 (In Russ.).
55. Monteiro da Silva J. L., Doimo G., Faria D. P. The use of high frequency waves to treat onychomycosis — preliminary communication of three cases. An. Bras. Dermatol. 2011; 86(3): 598–600. DOI: 10.1590/S0365-05962011000300033
56. Kutasevich Ya. F., Olіinik І. O., Rizhko P. P., Chekhovs’ka G. S., Mashtakova І. O., Zyuban І. V. Optimіzatsіya kompleksnoї terapії khvorikh na onіkhomіkozi. [Optimization of treatment of patients with onychomycosis]. Dermatologіya ta Venerologіya. 2014; 3(65): 82 (In Ukr.).
Review
For citations:
Tlish M.M., Shavilova M.E. MODERN TREATMENT OPTIONS OF TOENAIL ONYCHOMYCOSIS (A LITERATURE REVIEW). Kuban Scientific Medical Bulletin. 2019;26(2):202-213. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-2-202-213
Views:
760
Email this article 